Mark For: BUILT TO LAST™ trademark registration is intended to cover the categories of
Research | OneLook Acronym Finder |
Serial Number | 90182586 |
Mark Literal Elements | BUILT TO LAST |
Mark Drawing Type | 4 - STANDARD CHARACTER MARK |
Mark Type | TRADEMARK. SERVICE MARK |
Register | PRINCIPAL |
Current Location | INTENT TO USE SECTION 2021-11-09 |
Basis | 1(b) |
Class Status | ACTIVE |
Primary US Classes |
|
Primary International Class |
|
Filed Use | No |
Current Use | No |
Intent To Use | Yes |
Filed ITU | Yes |
44D Filed | No |
44E Current | No |
66A Current | No |
Current Basis | No |
No Basis | No |
Attorney Name | Marilyn F. Kelly |
Attorney Docket Number | 00156563-US |
2020-09-15 | Application Filed |
2020-09-18 | Location: NEW APPLICATION PROCESSING |
2020-09-18 | Status: Live/Pending |
2020-09-18 | Transaction Date |
2021-09-14 | Published |
2021-11-09 | Location: INTENT TO USE SECTION |
2022-12-12 | Status: Abandoned because no Statement of Use or Extension Request timely filed after Notice of Allowance was issued. To view all docume |
Party: | Bristol-Myers Squibb Company |
Address | 430 E. 29th Street, 14th Floor New York, NEW YORK UNITED STATES 10016 |
Legal Entity Type | Corporation |
Legal Entity State | DELAWARE |
Application | 2020-09-15 | |
Drawing | 2020-09-15 | |
Offc Action Outgoing | 2021-02-01 | |
XSearch Search Summary | 2021-02-01 | |
Response to Office Action | 2021-07-29 | |
Amendment and Mail Process Complete | 2021-07-31 | |
Examiners Amendment | 2021-08-05 | |
Amendment and Mail Process Complete | 2021-08-06 | |
TRAM Snapshot of App at Pub for Oppostn | 2021-08-06 | |
Notice of Publication | 2021-08-26 | |
Notification Of Notice of Publication | 2021-08-26 | |
Notification Of Notice of Publication | 2021-08-26 | |
Notification Of Notice of Publication | 2021-08-26 | |
OG Publication Confirmation | 2021-09-14 | |
OG Publication Confirmation | 2021-09-14 | |
OG Publication Confirmation | 2021-09-14 | |
Notice of Allowance | 2021-11-09 | |
Extension of Time to File SOU | 2022-05-06 | |
ITU Extension Approval | 2022-05-10 | |
ITU Unit Action | 2022-05-10 | |
Notice of Abandonment | 2022-12-12 | |
ITU Unit Action | 2022-12-13 |
(ABANDONED)
IC 005. US 005 006 018 044 046 051 052. G & S: Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely, T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for human use for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for use in disease testing(ABANDONED)
IC 016. US 002 005 022 023 029 037 038 050. G & S: Printed matter, namely, magazines, books, booklets, brochures, pamphlets, newsletters and catalogs in the field of pharmaceutical preparations for the treatment of cancer(ABANDONED)
IC 044. US 100 101. G & S: Medical information services, namely, providing medical information to physicians, health care professionals, and patients on the topic of cancer
International Codes: | 5 |
U.S. Codes: | 006,018,044,046,051,052 |
International Codes: | 16 |
U.S. Codes: | 002,005,022,023,029,037,038,050 |
International Codes: | 44 |
U.S. Codes: | 100,101 |
Type Code | Type |
---|---|
GS0051 | Pharmaceutical preparations for human use |
Description | Date | Proceeding Number |
---|---|---|
ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | 2022-12-12 | |
ABANDONMENT - NO USE STATEMENT FILED | 2022-12-12 | 99999 |
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 2022-05-10 | |
TEAS EXTENSION RECEIVED | 2022-05-06 | |
SOU EXTENSION 1 GRANTED | 2022-05-06 | 98765 |
SOU EXTENSION 1 FILED | 2022-05-06 | 98765 |
NOA E-MAILED - SOU REQUIRED FROM APPLICANT | 2021-11-09 | |
PUBLISHED FOR OPPOSITION | 2021-09-14 | |
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | 2021-09-14 | |
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | 2021-08-26 | |
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | 2021-08-05 | 6328 |
EXAMINERS AMENDMENT E-MAILED | 2021-08-05 | 6328 |
EXAMINERS AMENDMENT -WRITTEN | 2021-08-05 | 78048 |
EXAMINER'S AMENDMENT ENTERED | 2021-08-05 | 88888 |
APPROVED FOR PUB - PRINCIPAL REGISTER | 2021-08-05 | |
TEAS/EMAIL CORRESPONDENCE ENTERED | 2021-07-30 | 88889 |
TEAS RESPONSE TO OFFICE ACTION RECEIVED | 2021-07-29 | |
CORRESPONDENCE RECEIVED IN LAW OFFICE | 2021-07-29 | 88889 |
NOTIFICATION OF NON-FINAL ACTION E-MAILED | 2021-02-01 | 6325 |
NON-FINAL ACTION WRITTEN | 2021-02-01 | 78048 |
NON-FINAL ACTION E-MAILED | 2021-02-01 | 6325 |
ASSIGNED TO EXAMINER | 2021-01-27 | 78048 |
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | 2020-10-22 | |
NEW APPLICATION ENTERED IN TRAM | 2020-09-18 | |
NEW APPLICATION ENTERED | 2020-09-18 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.